WHITE PLAINS, NY, SEPTEMBER 20, 2005 -- ORTHOMETRIX, INC. (OTCBB: OMRX) announced today that it started selling in the United States its new Orbasone™ ESWT Pain Relief System which received market approval from the U.S. Food and Drug Administration (“FDA”) for the treatment of chronic plantar fasciitis (foot pain) on August 10, 2005.

The Orbasone™ ESWT system uses high-energy shock waves to relieve chronic plantar fasciitis. The technology is derived from a proven non-invasive technology called Extracorporeal Shock Wave Therapy, or ESWT, that has been used for the past 20 years to break up kidney stones without the use of surgery (lithotripsy). Plantar fasciitis is an inflammation of the plantar fascia, the thick strand of collagen which is located under the foot and connects the calcaneus (heel bone) to the metatarsals. This condition is extremely painful and reduces mobility and quality of life. It affected approximately 38.6 million Americans in 2000 according to the American Podiatric Medical Association (mainly athletes and the elderly).

One of the first Orbasone™ ESWT units has been sold to Manhattan Podiatry Associates, a prominent practice with several offices in New York City, specializing in the medical, surgical, laser treatment and ESWT of the foot. This practice was the East Coast site for the Orbasone™ ESWT clinical study. Chief physicians Drs. J. E. Mancuso and S. Abramow are board certified by the American Board of Podiatric Surgery and Fellows of the American College of Foot and Ankle Surgeons. They have been on the forefront of reconstruction and laser surgery of the foot, acquiring an international reputation as lecturers, authors of scientific publications and frequently quoted in non-scientific media. They have been instrumental in successfully completing the FDA clinical study to demonstrate the safety and efficacy of the Orbasone™ ESWT system for the treatment of chronic foot pain caused by plantar fasciitis. Orthometrix expects that, in addition to purchasing the Orbasone™ ESWT system, Manhattan Podiatry Associates will act as a reference site in the New York City area to promote the Orbasone™ ESWT system to podiatrists and orthopedic surgeons. Orthometrix would than have four sites that it can use as reference and for demonstration in New York, Pennsylvania, Illinois and California.

Commenting on the Orbasone™ ESWT system, Reynald Bonmati, Chairman and Chief Executive Officer of the Company, stated “I am very pleased with the interest the Orbasone™ ESWT system has already generated among podiatrists and orthopedic surgeons since it received market approval from the FDA last month. We have recruited a direct sales force for the Orbasone™ ESWT system that is now covering the entire country. With four locations that will be used not only as reference sites but also to bring potential users to check the outstanding performance of the Orbasone™ ESWT system, I have great expectations for this device. We are currently assembling units in Connecticut and building inventory to respond to the expected demand. The Orbasone™ ESWT system is the only ESWT device approved in the United States by the FDA for the treatment of chronic plantar fasciitis that is also manufactured in the United States. Our intent is to make ESWT treatment more affordable to a larger segment of the U.S. population.”

Orthometrix, Inc. (the “Company”) markets, sells and services several musculoskeletal product lines used in pharmaceutical research, diagnostics and monitoring of bone and muscle disorders, sports medicine, rehabilitative medicine, physical therapy and pain management.

Our Web addresses are www.orthometrix.net, www.vibraflex.com and www.orbasone.com

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this release are forward-looking statements that involve risk and uncertainties, including, but not limited to acceptance and demand for new products, he impact of competitive products and pricing, the regulatory environment, any effect on future financial results from efforts to broaden the Company’s position in the rehabilitation, physical therapy and musculoskeletal markets, any potential impact on sales of the Orbasone in North America, and other risks and uncertainties detailed in the documents periodically filed with the Securities and Exchange Commission, such as the Company’s most recent reports on Forms 10-KSB , 10-QSB ad 8-K. These risks and uncertainties could cause actual results to differ materially from those expected and/or contained in the forward-looking statements. Any forward-looking statement made in this release is made as of the date of this release and the Company assumes no obligation, subject to applicable law, to update such forward-looking statement.

###